Corporate Events

Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from FTSE All-World Index (USD)

Nippon Shinyaku Co., Ltd. has exercised its option rights under the option agreement entered into with AB2 BIO Ltd. in January 2025 regarding Tadekinig alfa. Through the exercise of the option rights, Nippon Shinyaku has obtained exclusive commercialization rights for Tadekinig alfa in the United States for the treatment of monogenic IL-18 driven Hyperinflammatory Syndrome in patients with NLRC4 and XIAP mutations. Tadekinig alfa has received Orphan Drug Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation in the United States, as well as Orphan Drug Designation in Europe. Following regulatory approval in the United States, Tadekinig alfa is expected to be commercialized by NS Pharma Inc. a wholly owned subsidiary of Nippon Shinyaku.

Nippon Shinyaku Co., Ltd., ¥ 62.0, Cash Dividend, Sep-29-2026

Nippon Shinyaku Co., Ltd., Board Meeting, Jul 21, 2026. Agenda: To consider and approve the Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation.

Nippon Shinyaku Co., Ltd., Q1 2027 Earnings Call, Aug 06, 2026

Nippon Shinyaku Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026

Nippon Shinyaku Co., Ltd. has entered into a Sponsored Research Agreement with Boston Children's Hospital for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement was facilitated by the NS Pharma Innovation Research Partnering team, located in Cambridge, MA. Following the initiation of the strategic collaboration announced in July 2025, Nippon Shinyaku has selected key research themes as proposed by Boston Children's Hospital as joint research programs. Through co-creation, Nippon Shinyaku will integrate Boston Children's Hospital's world class research capabilities with the company's drug discovery expertise to accelerate the creation of new neurologic therapeutic options for patients with unmet medical needs.

Nippon Shinyaku Co., Ltd. expected to report Q1 2027 results on August 7, 2026. This event was calculated by S&P Global (Created on May 19, 2026).

Capricor Therapeutics, Inc. announced that it has filed a Complaint for Equitable Relief and Application for Preliminary Injunction in the Superior Court of New Jersey, Chancery Division, Bergen County. The Lawsuit alleges a fundamental pricing flaw in the Commercialization and Distribution Agreement dated January 24, 2022, between the Company and Nippon Shinyaku Co. Ltd. The Lawsuit also seeks relief from Nippon Shinyaku Co. Ltd.'s U.S. subsidiary, NS Pharma. The Lawsuit alleges that NS have failed to adequately prepare for the commercial launch of the Company's product Deramiocel in the United States and have otherwise materially breached the terms of the U.S. Distribution Agreement. The Company seeks rescission of the U.S. Distribution Agreement, declaratory judgment that the Company has the right to distribute Deramiocel directly or through distributors other than NS, preliminary injunctive relief, and other equitable remedies. Capricor has spent two decades developing Deramiocel, a first-in-class cell therapy that represents one of the most significant therapeutic advances for DMD. In a rigorous Phase 3 clinical trial, Deramiocel slowed the progression of skeletal muscle deterioration by approximately 54% and slowed cardiac decline by approximately 91% compared to placebo both with statistical significance. Capricor brings this action because, absent intervention by the Court, the Deramiocel launch will be delayed and disrupted by Defendants NS Pharma and Nippon Shinyaku. And Deramiocel will likely become unavailable to help desperate patients in need due to the Distribution Agreements pricing structure which renders commercialization nonviable. In January 2022, Capricor entered into the Distribution Agreement with Nippon Shinyaku, granting it and its U.S. subsidiary, NS Pharma, the exclusive right to distribute Deramiocel in the United States. The Distribution Agreement contains a fatal flaw. The parties agreed on a pricing structure for distributing Deramiocel in Exhibit A to the Distribution Agreement, but upon information and belief, neither party understood at the time that the agreed-upon structure was not viable. Upon information and belief, the parties mutual mistake was that the interaction between the Distribution Agreements pricing formula and the federal Medicare reimbursement framework ensures that, in a very short time, neither party can afford to manufacture, distribute, sell, or administer Deramiocel to patients covered by Medicare, and healthcare providers will not be able to afford Deramiocel for administration to their patients in need. Because the federal Medicare program has a strong influence in setting prices that state Medicaid programs and private insurers pay for drugs, this flawed pricing structure will also make it economically impracticable to distribute Deramiocel to patients covered by Medicaid or private insurance. Simply put, neither Capricor nor the Distributor can afford to sell the medicine at a price much lower than the costs of making and distributing it. The Distributor neglected the key elements for a successful launch: it did not complete an acceptable gross-to-net revenue model based on the Distribution Agreement, and to this day, still has not shared one with Capricor. It has not established a realistic wholesale price. To Capricors knowledge, the Distributor has not conducted a single mock launch exercise. It has also arranged to enter into subdistribution agreements with third partiesessentially farming out contractual dutieswithout Capricors written consent as agreed upon. Over a period of roughly one year, through a series of detailed written requests and meetings, including direct engagement with NS Pharmas and Nippon Shinyakus most senior leadership, Capricor has asked the Distributor to show that it could fulfill its distribution obligations for Deramiocel. But the Distributors sporadic and incomplete answers only confirmed Capricors concerns. The Distributor was not adequately preparing for commercial launch, and was not being transparent with Capricor.

Nippon Shinyaku Co., Ltd., Annual General Meeting, Jun 26, 2026.

Nippon Shinyaku Co., Ltd., Q4 2026 Earnings Call, May 15, 2026

Nippon Shinyaku Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026

FY2025 Small Meeting

FY2025 R&D Meeting

Nippon Shinyaku Co., Ltd. at a meeting of its Board of Directors held on February 9, 2026, announced Director scheduled to retire: Takashi Takaya, Director, Personnel, General Affairs, Risk Management, Compliance & Digital Transformation (Current).

Nippon Shinyaku Co., Ltd. provided earnings guidance for the full year ending March 31, 2026. For the year, the company expects revenue to be JPY 170,000 million, operating profit to be JPY 33,000 million, Profit attributable to owners of the parent to be JPY 26,300 million or basic earnings per share to be JPY 390.20.

Nippon Shinyaku Co., Ltd. announced dividend for second quarter year ending March 31, 2026. For the period, the company announces dividend of JPY 62.00 per share compared to JPY 62.00 per share a year ago.

Nippon Shinyaku Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 127,135 million compared to JPY 121,320 million a year ago. Net income was JPY 25,844 million compared to JPY 28,552 million a year ago. Basic earnings per share from continuing operations was JPY 383.5 compared to JPY 423.93 a year ago. Diluted earnings per share from continuing operations was JPY 383.5 compared to JPY 423.84 a year ago.

Nippon Shinyaku Co., Ltd., Board Meeting, Feb 09, 2026. Agenda: To consider the Newly Appointed Director; to consider the reappointed director; and to consider the Scheduled for Promotion; and to consider the other matters.

Nippon Shinyaku Co., Ltd., Q3 2026 Earnings Call, Feb 09, 2026

Nippon Shinyaku Co., Ltd. expected to report Fiscal Year 2026 results on May 15, 2026. This event was calculated by S&P Global (Created on May 13, 2026).

Nippon Shinyaku Co., Ltd. announced second quarter end dividend for the six months ended September 30, 2025. For the period, the company announced Dividend of JPY 62.00 per share compared to JPY 62.00 per share a year ago. Scheduled start of payment: December 5, 2025.

Nippon Shinyaku Co., Ltd. provided earnings guidance for the full year ending March 31, 2026. For the year, the company expects revenue to be JPY 168,000 million, operating profit to be JPY 33,000 million, Profit attributable to owners of the parent to be JPY 26,300 million or basic earnings per share to be JPY 390.20.

Nippon Shinyaku Co., Ltd., ¥ 62.0, Cash Dividend, Mar-30-2026